Gufic Biosciences Limited (GUFICBIO) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Gufic Biosciences Limited ₹73.40, price ₹432, upside -83.0%, quality 45 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Structural break:
The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.
Weakest SetupStrongly overvalued and low quality.
!Fair value ₹73.40 · Strongly overvalued (−83.0%)
!Quality 45/100
!Expensive Growth(revenue 5y +14.1 %/yr)
!Thin margins · 6.8% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers(5/13)
!Moderate moat46/100
!Evidence only low, so the estimate is less certain
Watch Gufic Biosciences Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range ₹165.10 – ₹485.32 · fair‑value band ₹49.34 – ₹125.21 · the ₹432.00 price screens above the ₹73.40 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Gufic Biosciences in your weekly email
Every Wednesday you see whether Gufic Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America.
Show more
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs) segments. In addition, the company offers criti care, criticare life, ferticare, and spark pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. Further, it engages in contract and bulk drug manufacturing business. Gufic Biosciences Limited was founded in 1970 and is based in Mumbai, India.
Stock analysis
Gufic Biosciences Limited (GUFICBIO) currently trades at ₹432.00, while our model-based Fair Value estimate is ₹73.40, 83.0% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ₹212.70 per share, and 0 of the 17 models we run sit above the ₹432.00 price.
Bear case: the Asset-Based group reads lowest at ₹44.43, and 17 of the 17 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹49.34 (bear) to ₹125.21 (bull), the price of ₹432.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Gufic Biosciences Limited reported revenue of ₹9.4B in FY2026 versus ₹7.8B in FY2022, a compound +4.9%/yr. Reported net income was ₹642M in FY2026, compounding −9.5%/yr from FY2022.
Key figures
Market cap ₹43.3B (≈ $452M) · P/E ratio 67.6 · P/S ratio 4.60 · EPS (TTM) ₹6.39 · Dividend yield 0.0% · Net margin 6.8% · Return on equity 10.1% · Return on assets (EBIT) 19.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 4% below its 52-week high and 58% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −83%, GUFICBIO screens richer than that median.
Fair Value models
Bear ₹49.34Fair Value ₹73.40Bull ₹125.21
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹3.17 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+15.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.1%
Start year 2021 (pandemic). Over 10 years: +17.0% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.9%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+7.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+7.0%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.7.0% vs 21.1%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 13%
Compare Gufic Biosciences Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 619 stocks
Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score45 · Below median
Fair Value upside−83.0% · Bottom 25%
Profitability
Return on equity (TTM)10.1% · Above median
Return on assets6.0% · Above median
Net margin (TTM)6.8% · Above median
Operating margin (TTM)15.7% · Above median
Growth and dividend
Revenue growth22.8% · Top 25%
Dividend yield (TTM)0.0% · Bottom 25%
Balance sheet
Debt / equity0.16× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)67.6× · Priciest 25%
P/B6.52× · Priciest 25%
P/S (TTM)4.59× · Priciest 25%
EV/EBITDA28.8× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 14
FUTURE (revenue growth)100· sector 21
PAST (return on equity)41· sector 26
HEALTH (low debt)92· sector 96
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Gufic Biosciences Limited (GUFICBIO) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of ₹73.40 versus a price of ₹432.00, about −83% upside (overvalued).
What is the fair value of GUFICBIO?
Our model-based fair value for Gufic Biosciences Limited is ₹73.40 (as of Sep 27, 2026), built from audited fundamentals. The current price: ₹432.00.
What is the quality score of GUFICBIO?
Gufic Biosciences Limited has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Gufic Biosciences Limited (GUFICBIO)?
Our model-based price target is the fair value of ₹73.40 (as of Sep 27, 2026) from 17 valuation models. Cautious scenario ₹49.34, optimistic scenario ₹125.21. It is a calculation from audited fundamentals, not an analyst target.
What is the Gufic Biosciences Limited stock forecast for 2026?
Our models put fair value at ₹73.40, about −83% upside versus a price of ₹432.00 (overvalued). Cautious scenario ₹49.34, optimistic scenario ₹125.21. The calculation is refreshed regularly with new filings.
What is the revenue of Gufic Biosciences Limited (GUFICBIO)?
Gufic Biosciences Limited reported trailing-twelve-month revenue of about ₹9.4B (latest available figure, as of Sep 27, 2026).
Does Gufic Biosciences Limited pay a dividend?
Gufic Biosciences Limited currently shows a dividend yield of about 0.02% relative to its recent price (as of Sep 27, 2026).
What is the intrinsic value of Gufic Biosciences Limited (GUFICBIO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Gufic Biosciences Limited it is ₹73.40 per share (as of Sep 27, 2026), against a price of ₹432.00. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is Gufic Biosciences Limited stock overvalued or undervalued in 2026?
As of Sep 27, 2026, GUFICBIO trades above its calculated fair value: price ₹432.00, fair value ₹73.40, a gap of about −83% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GUFICBIO?
No. The price is what the market pays today (₹432.00); the fair value is what the company's own numbers justify (₹73.40). For Gufic Biosciences Limited the two are ₹358.60 per share apart. That gap is exactly why we show both numbers side by side.
How much is Gufic Biosciences Limited worth?
The market values Gufic Biosciences Limited at about ₹43.3B (market capitalisation, as of Sep 27, 2026). Per share that is ₹432.00; our models calculate a fair value of ₹73.40 per share.
What do the bullish and bearish scenarios say about GUFICBIO?
Our models span a range for Gufic Biosciences Limited: cautious scenario ₹49.34, base ₹73.40, optimistic ₹125.21 per share (as of Sep 27, 2026, price ₹432.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of GUFICBIO?
Gufic Biosciences Limited trades at a price-to-earnings ratio of 67.6 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹73.40 is built from several models across several years. Other multiples: P/B 6.5, P/S 4.6, EV/EBITDA 28.8.
How solid is the balance sheet of Gufic Biosciences Limited (GUFICBIO)?
Balance-sheet figures for Gufic Biosciences Limited (as of Sep 27, 2026): return on equity 10.1%, debt of 0.16 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is GUFICBIO from its 52-week high?
Gufic Biosciences Limited trades at ₹432.00, about 4% below its 52-week high of ₹448.00 and 58% above the low of ₹273.50 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of ₹73.40 is for.
Which stocks are comparable to Gufic Biosciences Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Gufic Biosciences Limited stock attractive at the current price?
The data as of Sep 27, 2026: price ₹432.00, calculated fair value ₹73.40 (−83%), Quality Score 45/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GUFICBIO calculated?
We run Gufic Biosciences Limited through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹73.40, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Gufic Biosciences Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Gufic Biosciences Limited (GUFICBIO)?
The closing price on Sep 30, 2026 was ₹432.00. Our model-based fair value is ₹73.40, about −83% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Gufic Biosciences Limited right now?
The price sits above even our optimistic bull case (₹125.21). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹49.34 to ₹125.21) leaves room in how you read the outcome.
Where does the earnings growth of Gufic Biosciences Limited (GUFICBIO) come from?
Earnings per share at Gufic Biosciences Limited grew +26.6 % a year from 2015 to 2026. Broken into its drivers: revenue per share +14.7 %, EBIT margin +14.8 %, tax rate +1.4 %, residual (interest, one-offs) −5.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Gufic Biosciences Limited
How large is the market capitalisation of Gufic Biosciences Limited (GUFICBIO)?
The market capitalisation of Gufic Biosciences Limited is ₹43.3B (≈ $452M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Gufic Biosciences Limited (GUFICBIO)?
The price-to-sales ratio of Gufic Biosciences Limited is 4.60 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Gufic Biosciences Limited (GUFICBIO)?
Earnings per share at Gufic Biosciences Limited are ₹6.39 (price ÷ EPS = P/E 67.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Gufic Biosciences Limited (GUFICBIO)?
The dividend yield of Gufic Biosciences Limited is 0.0% (payout 1.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Gufic Biosciences Limited (GUFICBIO)?
The net margin of Gufic Biosciences Limited is 6.8% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Gufic Biosciences Limited (GUFICBIO)?
The return on equity (ROE) of Gufic Biosciences Limited is 10.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Gufic Biosciences Limited (GUFICBIO)?
On an EBIT basis the return on assets of Gufic Biosciences Limited is 19.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Gufic Biosciences Limited (GUFICBIO)?
The operating margin of Gufic Biosciences Limited is 15.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Gufic Biosciences Limited (GUFICBIO)?
Revenue at Gufic Biosciences Limited is growing +22.8% versus a year earlier (3y avg +11.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Gufic Biosciences Limited (GUFICBIO)?
Earnings per share at Gufic Biosciences Limited are growing +183% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Gufic Biosciences Limited (GUFICBIO) generate?
The free cash flow of Gufic Biosciences Limited is −₹180M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Gufic Biosciences Limited (GUFICBIO) carry?
The net debt of Gufic Biosciences Limited is ₹3.3B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Gufic Biosciences Limited in the live analysis
One click puts Gufic Biosciences Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
